Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Change in Accured Expenses (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Change in Accured Expenses for 6 consecutive years, with -$3.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 192.16% to -$3.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$7.2 million, a 259.44% decrease, with the full-year FY2025 number at -$7.2 million, down 259.44% from a year prior.
  • Change in Accured Expenses was -$3.4 million for Q4 2025 at TScan Therapeutics, down from -$1.1 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $3.7 million in Q4 2024 to a low of -$5.4 million in Q1 2025.
  • A 5-year average of $256250.0 and a median of $760000.0 in 2023 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: surged 199.82% in 2021, then plummeted 317.37% in 2024.
  • TScan Therapeutics' Change in Accured Expenses stood at $1.8 million in 2021, then decreased by 28.37% to $1.3 million in 2022, then decreased by 0.91% to $1.3 million in 2023, then surged by 179.33% to $3.7 million in 2024, then tumbled by 192.16% to -$3.4 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Change in Accured Expenses are -$3.4 million (Q4 2025), -$1.1 million (Q3 2025), and $2.7 million (Q2 2025).